Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
Pearsanta’s Mitomic® technology is a platform that is designed to use mitochondrial DNA to identify biomarkers and to develop tests for early detection of cancer and other diseases. Pearsanta is currently conducting clinical validation of the first two tests that have been developed based on this technology for early detection of prostate cancer and endometriosis. MOT™ will potentially be another blood-based test to be added to the Company’s product pipeline designed for earlier detection of ovarian cancer. Ovarian cancer currently has a poor prognosis due to the fact that it is typically detected in later stages. Early detection of ovarian cancer can potentially improve the outcomes for women who face this terrible disease. Pearsanta submitted a pre-proposal on June 10, 2025, which was favorably reviewed for its scientific merit, level of innovation, alignment with OCRP Areas of Interest, and potential impact. The full proposal, titled “Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Ovarian Cancer,” is currently under development and will be submitted by the September 11, 2025, deadline.
The OCRP Pilot Award offers up to
“Early detection is one of the greatest unmet needs in ovarian cancer care,” said Chris Mitton, President of Pearsanta. “Our Mitomic® Ovarian Test has the potential to enable timely, more effective interventions, improve survival rates, and ultimately save lives. If successful, it could change the standard of care by offering a simple blood test that detects ovarian cancer at an earlier, more treatable stage—potentially improving survival and quality of life for women.”
The study aims to further develop and validate the MOT™ at Pearsanta’s
“Pearsanta’s continued progress is a powerful validation of our mission to accelerate promising health innovations with real-world impact,” said Amro Albanna, CEO of Aditxt. “We believe the Mitomic® platform has the potential to transform how diseases are detected and managed. Supporting the development of the MOT™ reflects our broader strategy to Acquire high-potential innovations, Build them into clinically and commercially viable solutions, and Capitalize their value to drive scalable deployment globally.
About Pearsanta
Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid, biopsy tests. Pearsanta's asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit www.pearsanta.com.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women’s health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem’s shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to the potential success of Pearsanta’s proposal for the
For more information, please visit www.aditxt.com.
Follow Aditxt on:
LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250724627121/en/
Investor and Media Contact
IR@aditxt.com
Source: Aditxt, Inc.
